CN102906108B - 用于无变性制备可溶性重组干扰素蛋白的方法 - Google Patents

用于无变性制备可溶性重组干扰素蛋白的方法 Download PDF

Info

Publication number
CN102906108B
CN102906108B CN201180021026.9A CN201180021026A CN102906108B CN 102906108 B CN102906108 B CN 102906108B CN 201180021026 A CN201180021026 A CN 201180021026A CN 102906108 B CN102906108 B CN 102906108B
Authority
CN
China
Prior art keywords
interferon
protein
extraction
recombinant
insoluble fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180021026.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102906108A (zh
Inventor
J·艾伦
冯平华
A·帕特卡
K·L·黑尼
L·丘
L·L·P·森钱萨朗希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phonex Corp
Original Assignee
Phonex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phonex Corp filed Critical Phonex Corp
Publication of CN102906108A publication Critical patent/CN102906108A/zh
Application granted granted Critical
Publication of CN102906108B publication Critical patent/CN102906108B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180021026.9A 2010-03-04 2011-03-02 用于无变性制备可溶性重组干扰素蛋白的方法 Expired - Fee Related CN102906108B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31067110P 2010-03-04 2010-03-04
US61/310,671 2010-03-04
PCT/US2011/026921 WO2011109556A2 (en) 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing

Publications (2)

Publication Number Publication Date
CN102906108A CN102906108A (zh) 2013-01-30
CN102906108B true CN102906108B (zh) 2016-01-20

Family

ID=44531690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180021026.9A Expired - Fee Related CN102906108B (zh) 2010-03-04 2011-03-02 用于无变性制备可溶性重组干扰素蛋白的方法

Country Status (16)

Country Link
US (2) US9187543B2 (enExample)
EP (1) EP2542574B1 (enExample)
JP (1) JP5840148B2 (enExample)
KR (1) KR101857825B1 (enExample)
CN (1) CN102906108B (enExample)
AU (1) AU2011223627B2 (enExample)
BR (1) BR112012022292A2 (enExample)
CA (1) CA2791361C (enExample)
CL (1) CL2012002378A1 (enExample)
CO (1) CO6592086A2 (enExample)
ES (1) ES2639398T3 (enExample)
MX (1) MX2012010148A (enExample)
NZ (1) NZ602255A (enExample)
PE (1) PE20130557A1 (enExample)
RU (1) RU2573909C2 (enExample)
WO (1) WO2011109556A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130557A1 (es) 2010-03-04 2013-05-19 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104151420A (zh) * 2013-05-15 2014-11-19 复旦大学 长效干扰素及其制备方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN107099569B (zh) * 2017-06-30 2021-05-07 北京生物制品研究所有限责任公司 一种规模化发酵生产重组人干扰素β1b蛋白的方法
CN116194460A (zh) * 2020-06-09 2023-05-30 Icosavax股份有限公司 制备病毒样颗粒的方法
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939212A1 (en) * 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US5702699A (en) * 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) * 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695455A (en) * 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) * 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5128130A (en) * 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) * 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5169760A (en) * 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU8735991A (en) 1990-09-28 1992-04-28 Ortho Pharmaceutical Corporation Hybrid growth factors
US5508192A (en) * 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5240834A (en) * 1991-01-22 1993-08-31 Albert Einstein College Of Medicine Of Yeshiva University Solubilization of protein after bacterial expression using sarkosyl
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
RU2098124C1 (ru) * 1994-10-24 1997-12-10 Общество с ограниченной ответственностью "Ниготек" Способ получения интерферона
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE69815707T2 (de) * 1997-11-20 2004-07-01 Vical, Inc., San Diego Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
WO1999058662A1 (fr) 1998-05-14 1999-11-18 Merck Patent Gmbh Proteine fusionnee
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
WO2000049146A1 (en) 1999-02-18 2000-08-24 Rmf Dictagene S.A. Malaria vaccine
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
KR100358948B1 (ko) * 2000-03-31 2002-10-31 한국과학기술원 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
JP4799803B2 (ja) 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
PL209928B1 (pl) * 2000-11-07 2011-11-30 Novartis Vaccines & Diagnostic Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β
RU2003125641A (ru) 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный колониестимулирующий гранулоцитарный фактор (g-csf) с уменьшенной иммуногенностью
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
WO2003023050A2 (en) * 2001-09-10 2003-03-20 Emd Biosciences, Inc. Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first
US20040247562A1 (en) 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
AU2003267827A1 (en) 2002-08-31 2004-03-19 Cj Corp. Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8399217B2 (en) * 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
JP5087741B2 (ja) 2003-11-19 2012-12-05 フェネックス インコーポレイテッド 改良タンパク質発現系
AU2004317306B2 (en) * 2003-11-21 2010-09-02 Pelican Technology Holdings, Inc. Improved expression systems with Sec-system secretion
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
AU2005206951B2 (en) 2004-01-16 2010-08-19 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2008507294A (ja) * 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
CA2591235C (en) * 2004-12-20 2014-03-11 Cadila Healthcare Limited Process for preparing high levels of interferon beta
WO2006067170A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
GB0605684D0 (en) 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2007142954A2 (en) * 2006-05-30 2007-12-13 Dow Global Technologies Inc. Codon optimization method
EP2468869B1 (en) * 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
EP2615172A1 (en) 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
EP3660032B1 (en) 2009-06-25 2025-10-22 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
PE20130557A1 (es) 2010-03-04 2013-05-19 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion
EP2552949B1 (en) * 2010-04-01 2016-08-17 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939212A1 (en) * 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Use of Zwittergent 3-14 in the Purification of Recombinant Human Interferon-β Ser17(Betaseron);Russell-Harde等;《J.Interferon and Cytokine Res.》;19950131;第15卷(第1期);31-37 *

Also Published As

Publication number Publication date
WO2011109556A3 (en) 2012-01-12
EP2542574B1 (en) 2017-08-09
CN102906108A (zh) 2013-01-30
NZ602255A (en) 2014-04-30
AU2011223627B2 (en) 2015-06-18
US20110217784A1 (en) 2011-09-08
EP2542574A4 (en) 2014-01-29
AU2011223627A1 (en) 2012-09-27
EP2542574A2 (en) 2013-01-09
PE20130557A1 (es) 2013-05-19
RU2012141653A (ru) 2014-04-10
US9187543B2 (en) 2015-11-17
US9611499B2 (en) 2017-04-04
CA2791361A1 (en) 2011-09-09
JP2013524775A (ja) 2013-06-20
CL2012002378A1 (es) 2014-01-10
KR20130018743A (ko) 2013-02-25
CO6592086A2 (es) 2013-01-02
RU2573909C2 (ru) 2016-01-27
BR112012022292A2 (pt) 2017-01-10
ES2639398T3 (es) 2017-10-26
JP5840148B2 (ja) 2016-01-06
MX2012010148A (es) 2013-01-22
CA2791361C (en) 2018-06-12
WO2011109556A2 (en) 2011-09-09
US20160032345A1 (en) 2016-02-04
KR101857825B1 (ko) 2018-05-14

Similar Documents

Publication Publication Date Title
US9611499B2 (en) Method for producing soluble recombinant interferon protein without denaturing
Del Tito Jr et al. Effects of a minor isoleucyl tRNA on heterologous protein translation in Escherichia coli
ES2952405T3 (es) Parejas de fusión para la producción de péptidos
CN102858981B (zh) 重组crm197的高水平表达
Bis et al. High yield soluble bacterial expression and streamlined purification of recombinant human interferon α-2a
KR101183720B1 (ko) 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
CN1230542C (zh) 通过自我蛋白水解生产蛋白质
US8709757B2 (en) Method for producing interferon alpha 5
US8236524B2 (en) Modified microorganism
Mobasher et al. Two step production of optimized interferon Beta 1b; A way to overcome its toxicity
KR100890187B1 (ko) Ｔｓｆ를 융합파트너로 이용한 재조합 단백질의 제조방법
EP2820040A1 (en) Method for reduction of 1->2 reading frame shifts
Yoon et al. Cloning and expression of soluble recombinant protein comprising the extracellular domain of the human type I interferon receptor 2c subunit (IFNAR-2c) in E. coli
Antunes Produção e Purificação do Interferão Alfa-2B a Partir de Culturas de Escherichia Coli Utilizando Plataformas Alternativas
KR940011533B1 (ko) 인터로이킨의 증수법
Salama et al. Interdisciplinary Gene Manipulation, Molecular Cloning, and Recombinant Expression of Modified Human Growth Hormone Isoform-1 in E. Coli System
MXPA06008061A (en) Expression of mammalian proteins in pseudomonas fluorescens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20200302

CF01 Termination of patent right due to non-payment of annual fee